These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31994193)

  • 1. Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis.
    Araujo RLC; Silva RO; de Pádua Souza C; Milani JM; Huguet F; Rezende AC; Gaujoux S
    J Surg Oncol; 2020 Apr; 121(5):881-892. PubMed ID: 31994193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
    Czosnyka NM; Borgert AJ; Smith TJ
    HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
    de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
    Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
    Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection and radiochemotherapy of pancreatic cancer--the future?
    Link KH; Formentini A; Leder G; Fortnagel G; Sartori N; Schatz M; Beger HG
    Langenbecks Arch Surg; 1998 Apr; 383(2):134-44. PubMed ID: 9641886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy in operable pancreatic cancer.
    Wente MN; Büchler P; Friess H; Büchler MW
    Swiss Surg; 2002; 8(2):74-80. PubMed ID: 12013694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.
    Denbo JW; Bruno ML; Cloyd JM; Prakash L; Lee JE; Kim M; Crane CH; Koay EJ; Krishnan S; Das P; Minsky BD; Varadhachary G; Shroff R; Wolff R; Javle M; Overman MJ; Fogelman D; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Gastrointest Surg; 2016 Dec; 20(12):1975-1985. PubMed ID: 27730398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review.
    Attard JA; Farrugia A; Pathanki A; Roberts KJ; Dasari B; Isaac J; Ma YT; Chatzizacharias NA
    Pancreas; 2020; 49(10):1264-1275. PubMed ID: 33122513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis.
    Araujo RL; Gaujoux S; Huguet F; Gonen M; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Jarnagin WR; Goodman KA; Allen PJ
    HPB (Oxford); 2013 Aug; 15(8):574-80. PubMed ID: 23458208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis.
    Uchida Y; Masui T; Nagai K; Anazawa T; Yoshimura M; Uza N; Takaori K; Mizowaki T; Uemoto S
    Surg Oncol; 2020 Dec; 35():527-532. PubMed ID: 33160278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
    BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications.
    Verma V; Li J; Lin C
    Am J Clin Oncol; 2016 Jun; 39(3):302-13. PubMed ID: 26950464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment.
    Paye F; Micelli Lupinacci R; Bachellier P; Boher JM; Delpero JR;
    Br J Surg; 2015 Feb; 102(3):229-36. PubMed ID: 25533421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
    Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
    Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.